| Citation: |
WANG Cuiyun, ZHAO Tong, FAN Guiling. Construction of a predictive model for ovulation induction therapy efficacy in polycystic ovary syndrome[J]. Journal of Clinical Medicine in Practice, 2024, 28(10): 116-120. DOI: 10.7619/jcmp.20240066
|
To analyze the influencing factors of ovulation induction therapy in patients with polycystic ovary syndrome (PCOS), and to construct a predictive model for the efficacy of ovulation induction therapy in PCOS patients.
A total of 200 infertile PCOS patients suitable for ovulation induction therapy were selected as the study subjects.All patients underwent ovulation induction with letrozole or letrozole combined with urinary gonadotropins. They were divided into effective group (n=160) and ineffective group (n=40) based on the efficacy of ovulation induction. The clinical data of the two groups were retrospectively collected and analyzed. Logistic regression analysis was used to analyze the influencing factors of ovulation induction therapy in PCOS patients, and a nomogram prediction model for the efficacy of ovulation induction was constructed. The predictive performance of the nomogram model for ovulation induction therapy in PCOS patients was evaluated.
The number of ovulations and mature follicles, proportion of ovulation patients and endometrial thickness in the effective group were significantly higher, and the androgen level in the effective group was significantly lower than that in the ineffective group (P<0.05). Logistic regression analysis showed that androgen level, ovulation count, the number of mature follicles and endometrial thickness were influencing factors for the efficacy of ovulation induction in PCOS patients (OR<1, P<0.05). Receiver operating characteristic (ROC) curve analysis revealed that the area under the curve (AUC) values for ovulation count, the number of mature follicles, endometrial thickness and androgen level in assessing the efficacy of ovulation induction therapy in PCOS patients were greater than 0.60. The verification results of the nomogram prediction model showed that the consistency index value of the calibration curve was 0.984.
Androgen level, ovulation count, the number of mature follicles and endometrial thickness areinfluencing factors for the efficacy of ovulation induction therapy in PCOS patients. The evaluation performance of the nomogram prediction model based on the above factors is good.
| [1] |
DETLEFSEN A J, PAULUKINAS R D, MESAROS C. High sensitivity LC-MS methods for quantitation of hydroxy- and keto-androgens[J]. Methods Enzymol, 2023, 689: 355-376.
|
| [2] |
HA L X, DU Y D, QU X X, et al. Correlation between hemoglobin levels and polycystic ovary syndrome metabolic disorder[J]. Diabetes Metab Syndr Obes, 2023, 16: 3019-3027. doi: 10.2147/DMSO.S430120
|
| [3] |
HU D L, WANG J M, CHENG T F, et al. Comparative analysis of serum and saliva samples using Raman spectroscopy: a high-throughput investigation in patients with polycystic ovary syndrome and periodontitis[J]. BMC Womens Health, 2023, 23(1): 522. doi: 10.1186/s12905-023-02663-y
|
| [4] |
LIM S, TAKELE W W, VESCO K K, et al. Participant characteristics in the prevention of gestational diabetes as evidence for precision medicine: a systematic review and meta-analysis[J]. Commun Med, 2023, 3(1): 137. doi: 10.1038/s43856-023-00366-x
|
| [5] |
AL-AKABI D F, HAFTH H A. Physiological effect of iron status on patients with polycystic ovary syndrome in Basrah city[J]. J Med Biochem, 2023, 42(3): 530-535. doi: 10.5937/jomb0-39091a
|
| [6] |
ALSAFFAR S F, IBRAHIM S K. Assessment of chemokines MIP-1α and MIP-1 βin Iraqi women with polycystic ovarian syndrome[J]. Egypt J Immunol, 2023, 30(4): 40-46. doi: 10.55133/eji.300405
|
| [7] |
FANGFANG WANG, JIEXUE PAN, YAN WU, et al. 关于美国、欧洲和中国的多囊卵巢综合征临床指南或共识的比较分析[J]. 浙江大学学报(英文版)(B辑: 生物医学和生物技术), 2018, 19(5): 354-363. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDYW201805004.htm
|
| [8] |
GÜNEŞ M, GÜNEŞ E, ÖZTÜRK F. Total testosterone cut-off value indicating androgen-secreting tumor in premenopausal women with hirsutism[J]. Eur Rev Med Pharmacol Sci, 2023, 27(18): 8681-8689.
|
| [9] |
DESHMUKH H, PAPAGEORGIOU M, WELLS L, et al. The effect of a very-low-calorie diet (VLCD) vs. a moderate energy deficit diet in obese women with polycystic ovary syndrome (PCOS)-a randomised controlled trial[J]. Nutrients, 2023, 15(18): 3872. doi: 10.3390/nu15183872
|
| [10] |
UNGUREANU M C, BILHA S C, HOGAS M, et al. Preptin: a new bone metabolic parameter?[J]. Metabolites, 2023, 13(9): 991. doi: 10.3390/metabo13090991
|
| [11] |
ZHAI J J, ZHANG J Y, HE J F, et al. Live birth outcomes for PCOS patients under the follicular-phase long-acting GnRH agonist protocol or antagonist protocol - A retrospective Chinese cohort[J]. J Multidiscip Healthc, 2023, 16: 2781-2792. doi: 10.2147/JMDH.S432936
|
| [12] |
ABD-ELWAHAB S A, KHAMIS N H, RIFAAI R A, et al. Mesenchymal-stem cell-derived conditioned media versus exosomes in the treatment of rat model of polycystic ovary: an attempt to understand the underlying mechanisms (biochemical and histological study)[J]. Microsc Microanal, 2023, 29(3): 1244-1257. doi: 10.1093/micmic/ozad046
|
| [13] |
SARATHI V, REDDY A, TIRUPATI S, et al. Acton-prolongatum stimulated blood steroid profile in apparently healthy Asian Indian women of reproductive-age group[J]. Indian J Clin Biochem, 2023, 38(4): 541-544. doi: 10.1007/s12291-022-01039-7
|
| [14] |
QUESADA O. Reproductive risk factors for cardiovascular disease in women[J]. Menopause, 2023, 30(10): 1058-1060. doi: 10.1097/GME.0000000000002264
|
| [15] |
ALQUTAMI F, HACHIM M, HODGMAN C, et al. Transcriptomic analysis identifies four novel receptors potentially linking endometrial cancer with polycystic ovary syndrome and generates a transcriptomic atlas[J]. Oncotarget, 2023, 14: 825-835. doi: 10.18632/oncotarget.28513
|
| [16] |
FINSTERER J. Polycystic ovary syndrome due to the novel translocation 46XX t(2; 9)(q21; p24)[J]. Arch Clin Cases, 2023, 10(3): 123-124. doi: 10.22551/2023.40.1003.10256
|
| [17] |
TOKTAY E, SELLI J, GURBUZ M A, et al. Investigation of the effects of astaxanthin in experimental polycystic ovary syndrome (PCOS) in rats[J]. Iran J Basic Med Sci, 2023, 26(10): 1155-1161.
|
| [18] |
HAMMAMI B, MOSTAFAVI F S, AKBARI A, et al. Evaluation of the expression profile of mRNAs and lncRNAs in cumulus cells associated with polycystic ovary syndrome and pregnancy[J]. Iran J Basic Med Sci, 2023, 26(10): 1144-1154.
|
| [19] |
KUMAR S, SENAPATI S, BHATTACHARYA N, et al. Mechanism and recent updates on insulin-related disorders[J]. World J Clin Cases, 2023, 11(25): 5840-5856. doi: 10.12998/wjcc.v11.i25.5840
|
| [20] |
BAHRAMIAN H, SHERAFATMANESH S, ASADI N, et al. Effects of single-dose and co-supplementation of vitamin D and omega-3 on metabolic profile in women with polycystic ovary syndrome: an RCT[J]. Int J Reprod Biomed, 2023, 21(7): 541-550.
|
| 1. |
郭云. 麻黄汤合止嗽散加减联合常规治疗对慢性阻塞性肺疾病急性加重期患者的临床疗效分析. 中国医药指南. 2024(09): 135-137 .
| |
| 2. |
张靖琨，陈兴慧，宋雪红，杨健伟，徐新松. 益肺化痰定喘汤加减结合西药治疗老年AECOPD对患者肺功能及气道黏液高分泌的影响. 现代中医药. 2024(03): 68-72 .
| |
| 3. |
陆薇. 穴位埋线联合茚达特罗/格隆溴铵对肺肾气虚型慢性阻塞性肺疾病的应用与研究. 中国医药科学. 2024(08): 82-85 .
| |
| 4. |
叶迎春，周亮，占中英. 升陷汤辅助治疗慢性阻塞性肺疾病急性加重期的临床观察. 现代诊断与治疗. 2023(01): 27-29 .
| |
| 5. |
刘方，刁素梅，严瑾，孙琴. 火龙罐辅治慢性阻塞性肺疾病急性发作期临床观察. 实用中医药杂志. 2023(09): 1793-1794 .
| |
| 6. |
贺小举. 桑菊清解汤联合穴位敷贴对慢性阻塞性肺疾病急性加重期痰热蕴肺证患者中医证候的影响. 中国实用医刊. 2023(18): 120-123 .
| |
| 7. |
李炬明. 补中益气汤加减联合沙美特罗替卡松治疗慢性阻塞性肺疾病急性加重期患者的临床研究. 实用中西医结合临床. 2022(13): 44-46 .
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: